Although this week’s quarterly earnings report for JONE came in a little better than expected, that wasn’t good enough to keep it from closing below its stop price so I have to close out this position. Read More
Jim Pearce is the Chief Investment Strategist of Personal Finance, our flagship publication, and manages two trading services, PF Pro and Mayhem Trader. He began his career as a stockbroker in 1983 and over the years has managed client investment portfolios for major banks, brokerage firms, and investment advisors. Jim earned a BA from The College of William & Mary and the CFP designation from the College of Financial Planning.
Analyst Articles
Doubts creep in over how much of his agenda the president can accomplish. Read More
With interest in so-called “Trump stocks” beginning to wane now that those campaign promises must fit into a budget, investors are beginning to look for value and a stock like HBI, trading at less than 10x forward earnings with an IDEAL score of 8, may be just what they are looking for. Read More
Buy the Synergy Pharmaceuticals (NSDQ: SGYP) April 21, 2017 $5.50 call option up to $0.60. Read More
I will continue to hold JONE with a revised stop price of $2.85 due to the Special Dividend declared last week. Read More
- March 3, 2017
-
Download Issue
What if you held a party and nobody came? RGR released fourth quarter and full-year 2016 results on February 22 that reflected a 21% increase in net sales and 43% jump in earnings per share, but even that wasn’t enough to break the stock out of its narrow trading… Read More
- March 3, 2017
-
Download Issue
I bought KSS in January on the belief that investors had overreacted to weak holiday sales figures from the retail sector, and based on Kohl’s better than feared quarterly report issued last week it appears that assumption is proving true. At the end of February we had a 3%… Read More
- March 3, 2017
-
Download Issue
I waited until after JONE released its full year guidance for 2017 before issuing our buy alert on February 23, believing that would remove most of the near-term risk in the stock. Turns out I was wrong about that, as its share price dropped more than 10% the following… Read More
- March 3, 2017
-
Download Issue
It’s been a rocky road during our first six weeks in this position, but we have managed to eke out a small gain in CVS despite a big drop the week after we bought it on January 26. After bottoming out below $75 on February 2, CVS climbed steadily upward… Read More
- March 3, 2017
-
Download Issue
CSCO was our top performing holding in February, gaining nearly 11% for the month which accounts for the bulk of its 12% increased since we added it to our portfolio on December 21. The month of January was fairly quiet until the company announced its proposed acquisition of AppDynamics, and since… Read More